source
- AstraZeneca's COPD drug cuts flare-ups in late-stage trials, offering new option for patientsIn two late-stage studies, an AstraZeneca therapy showed a statistically significant reduction in acute exacerbations that worsen chronic obstructive pulmonary disease. The data, released on Tuesda…
- Sandoz to invest $1 billion in European biosimilar hub, targeting 100 biosimilars by 2040Sandoz announced at its investor day that it will spend roughly $1 billion to build a fully integrated European biosimilar hub as part of a plan to bring more than 100 biosimilars to market by 2040…